We are live on ! Find out more
SCM

Suvretta Capital Management Portfolio holdings

AUM $3.92B
1-Year Est. Return 86.67%
This Fund
S&P 500
This Quarter Est. Return
+6.22%
1 Year Est. Return
+86.67%
3 Year Est. Return
+295.96%
5 Year Est. Return
+364.48%
10 Year Est. Return
+2,073.65%
AUM
$2.72B
AUM Growth
+$29.7M
Cap. Flow
+$160M
Cap. Flow %
5.89%
Top 10 Hldgs %
47.84%
Holding
110
New
9
Increased
24
Reduced
22
Closed
12

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$71.7M
2
BHVN icon
Biohaven
BHVN
+$47.3M
3
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$42.1M
4
SYY icon
Sysco
SYY
+$38.9M
5
AAPL icon
Apple
AAPL
+$34.8M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$48M
2
CI icon
Cigna
CI
+$45.6M
3
MCK icon
McKesson
MCK
+$30.5M
4
VZ icon
Verizon
VZ
+$23M
5
BCYC
Bicycle Therapeutics
BCYC
+$22.8M

Sector Composition

Rank Sector Weight
1 Healthcare 58.96%
2 Technology 10.09%
3 Communication Services 6.22%
4 Consumer Discretionary 5.49%
5 Financials 2.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GLUE icon
51
Monte Rosa Therapeutics
GLUE
$1.33B
$9.94M 0.37%
+2,659,000
New +$13.6M
ALNY icon
52
Alnylam Pharmaceuticals
ALNY
$28.9B
$9.14M 0.34%
37,624
+4,964
+15% +$784K
GEHC icon
53
GE HealthCare
GEHC
$31.8B
$5.84M 0.21%
75,000
– –
MRNS
54
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$4.47M 0.16%
3,820,012
-1,288,508
-25% -$3.22M
TEVA icon
55
Teva Pharmaceuticals
TEVA
$40.6B
$4.36M 0.16%
268,100
– –
KZR
56
DELISTED
Kezar Life Sciences
KZR
$4.3M 0.16%
716,759
– –
DHR icon
57
Danaher
DHR
$141B
$4.1M 0.15%
16,427
– –
TMO icon
58
Thermo Fisher Scientific
TMO
$214B
$4.01M 0.15%
7,260
– –
EXAS
59
DELISTED
Exact Sciences
EXAS
$3.98M 0.15%
+94,100
New +$5.18M
ELAN icon
60
Elanco Animal Health
ELAN
$12.1B
$3.66M 0.13%
253,600
-253,600
-50% -$4.05M
ABT icon
61
Abbott
ABT
$187B
$3.48M 0.13%
33,520
– –
GILD icon
62
Gilead Sciences
GILD
$162B
$3.48M 0.13%
50,700
– –
KVUE icon
63
Kenvue
KVUE
$36.8B
$3.12M 0.11%
171,596
– –
MOLN
64
Molecular Partners
MOLN
$152M
$2.89M 0.11%
400,000
– –
COR icon
65
Cencora
COR
$63.2B
$2.81M 0.1%
12,488
– –
MTD icon
66
Mettler-Toledo International
MTD
$28.5B
$2.74M 0.1%
1,964
– –
SYRE icon
67
Spyre Therapeutics
SYRE
$9.12B
$2.52M 0.09%
107,310
-55,085
-34% -$1.86M
ISRG icon
68
Intuitive Surgical
ISRG
$132B
$2.31M 0.09%
5,200
– –
TRML
69
DELISTED
Tourmaline Bio
TRML
$1.61M 0.06%
125,000
– –
CI icon
70
Cigna
CI
$72.7B
$1.59M 0.06%
4,800
-132,339
-96% -$45.6M
AVTR icon
71
Avantor
AVTR
$8.91B
$1.52M 0.06%
71,850
– –
IQV icon
72
IQVIA
IQV
$38.3B
$1.52M 0.06%
7,175
– –
SYK icon
73
Stryker
SYK
$129B
$1.48M 0.05%
4,360
– –
MDT icon
74
Medtronic
MDT
$110B
$1.37M 0.05%
17,460
– –
LKFT
75
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.71B
$1.17M 0.04%
47,200
– –
1 2
3
4 5

Similar funds

MIM
Meridiem Investment Management London, United Kingdom $3.92B AUM 1.64% 1-Year Est. Return
BCP
BSN Capital Partners London, United Kingdom $3.93B AUM 13.09% 1-Year Est. Return
AS
American Securities New York $3.93B AUM 52.22% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $3.9B AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $3.95B AUM 33.1% 1-Year Est. Return
GAMH
Greenwoods Asset Management (HK) Hong Kong $3.88B AUM 23.82% 1-Year Est. Return
TFM
Trian Fund Management New York $3.86B AUM 26.59% 1-Year Est. Return

Suvretta Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Suvretta Capital Management held 110 positions worth $2.72B, up 1.1% from $2.69B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Suvretta Capital Management deployed $160M of net new capital in Q2 2024, opening 9 new positions and adding to 24 existing holdings. Its largest new stake was Sysco: 520,900 shares worth $37.2M.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, up from 58% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Cigna, an estimated $45.6M trimmed.

  • Suvretta Capital Management's largest Q2 2024 buy was Sysco: 520,900 shares worth $37.2M.
  • Suvretta Capital Management added most to UnitedHealth in Q2 2024, an estimated $71.7M increase.
  • Suvretta Capital Management's biggest Q2 2024 reduction was Cigna, cutting an estimated $45.6M.
  • Suvretta Capital Management fully exited argenx in Q2 2024, selling an estimated $48M.
  • Suvretta Capital Management's ten largest holdings make up 48% of its $2.72B portfolio in Q2 2024.
  • Suvretta Capital Management opened 9 new positions and closed 12 in Q2 2024.
  • Suvretta Capital Management's portfolio value rose 1.1% quarter-over-quarter to $2.72B.

Based on Suvretta Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.